Depomed | DEPO

Depomed traded at $3.70 this Monday August 15th, decreasing $0.10 or 2.63 percent since the previous trading session. Looking back, over the last four weeks, Depomed lost 31.21 percent. Over the last 12 months, its price rose by 266.34 percent. Looking ahead, we forecast Depomed to be priced at 3.69 by the end of this quarter and at 3.39 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Daiichi Sankyo 4,169.00 -42.00 -1.00% 72.49%
Aurora Cannabis Inc 2.43 0.20 8.97% -70.65%
Aerie Pharmaceuticals 11.74 0.17 1.47% -18.87%
ANI Pharmaceuticals 37.84 0.37 0.99% 29.37%
Cara Therapeutics 11.75 0.24 2.09% -6.30%
Depomed 3.70 -0.10 -2.63% 266.34%
Knight Therapeutics Inc 6.12 0.06 0.99% 11.07%
Ironwood Pharmaceuticals 11.91 0.16 1.36% -10.92%
J&J 166.09 0.79 0.48% -6.61%
Merck & Co 90.60 -0.42 -0.46% 14.93%
Nektar Therapeutics 4.91 -0.23 -4.47% -64.34%
Omeros 6.74 -0.39 -5.47% -54.09%
Pfizer 49.75 -0.36 -0.72% 1.72%
Teva Pharmaceutical Industries Ltd 3,632.00 12.00 0.33% 14.61%

Indexes Price Day Year
USND 13128 80.87 0.62% -11.26%
US2000 2021 4.73 0.23% -8.26%

Depomed
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company's commercial portfolio of branded products focuses on three areas: neurology, hospital, and pain and inflammation. Its marketed products include Cambia (diclofenac potassium) for Oral solution, INDOCIN Oral Suspension, INDOCIN (indomethacin) Suppositories, OXAYDO (oxycodone HCI, USP) tablets, SPRIX (ketorolac tromethamine) Nasal Spray, and ZIPSOR (diclofenac potassium) Liquid filled capsules. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis. CAMBIA (diclofenac potassium) is used for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older.